BD Is Selling the World's Leading Blood Culture Franchise and Leaving Diagnostics

Editorial analysis accompanying the Global Microbiology Diagnostics Market Report, 2026–2033.

BD announced that its Diagnostic Solutions business — the segment that contains BACTEC blood culture, the BD MAX molecular platform and the COR streaking system — is to be combined with Waters Corporation around the end of the first quarter of calendar 2026. What remains is described by the company as a medtech business.

Read as a portfolio decision, that is unremarkable. Read as a statement about microbiology, it is the most informative thing any vendor in the discipline has said this cycle: the largest franchise in blood culture has concluded that its growth rate belongs in an analytical-instruments multiple rather than a diagnostics one.

What the segment actually contains

Diagnostic Solutions is not a marginal business. It holds the installed base that made blood culture a closed, recurring workflow: the bottles, the incubators, the identification step and the susceptibility determination that follows. Microbiology is a USD 8,830 million market in 2025 growing 5.14% to USD 13,190 million by 2033, and blood culture systems and consumables are its single largest class at USD 2,120 million.

But that class grows at 4.35%, and the culture media, specimen collection and processing class beside it grows at 2.62%. The culture block together — 43.26% of the discipline’s 2025 revenue — is the slowest large object in the report. Everything growing faster than five per cent is molecular, panelised or automated, and much of that growth happens on somebody else’s platform.

The number in BD’s own release that explains the decision

BD’s FY2025 results concede something that rarely appears in a segment discussion. US utilisation of its BACTEC, MAX and COR instruments, the company states, remains above only 85% of historical levels.

Translated: the installed base has not recovered its prior throughput. In a razor-and-blade franchise, utilisation is the leading indicator for consumable revenue — the bottles and panels are pulled through by tests actually run, not by analysers actually placed. An installed base running at 85% of its own history is a base generating 85% of the consumable pull it was built to generate, and no amount of new placement closes that gap quickly.

Two things follow. A franchise with a utilisation deficit and a 4.35% structural growth rate is a franchise whose earnings are better explained by its instrument and consumable economics than by a diagnostics growth story. And a franchise being rehomed into an analytical-instruments company is one whose consumable stream will be managed for cash rather than for menu expansion.

Why the timing is not accidental

The separation arrives in the same cycle as the largest administered price event microbiology has faced in the United States. CMS’s preliminary CY 2027 Clinical Laboratory Fee Schedule cuts 224 microbiology codes by a weighted median of 19.3%, phased at 15% a year through 2029. Of 1,528 priced codes in the schedule, 1,171 fall.

That cut lands on the customer’s revenue, not the vendor’s, in the first instance — but it reaches the vendor through the reagent contract, and it reaches a closed consumable franchise faster than an open one. When the price of the test is administered downward and the volume underneath is running below its own history, the rational corporate response is not to defend the category. It is to stop reporting it as a category.

What the discipline looks like afterwards

Microbiology’s vendor structure is unusual in this cluster because so much of it is estimated rather than disclosed. Aggregate attribution is 81.37% against an 18.63% residual — the lowest residual of any discipline report in the set — but hard disclosure is only 24.79%, and it is essentially one company: bioMérieux’s two application lines. BD’s pool at USD 1,180 million, Danaher and Cepheid at USD 760 million, Thermo Fisher at USD 640 million and Bruker at USD 520 million are all estimates.

So the vendor that anchors the largest share of the estimated pool is moving outside the perimeter in which its revenue was legible as diagnostics. The practical consequence for anyone modelling this market is a higher residual, not a smaller one: after the transaction, BD’s microbiology revenue has to be read out of an analytical-instruments segment that will not break it out.

What it means at the bench

Less than the headline suggests, and more than nothing.

Consumable supply, service obligations and validated performance claims travel with the product, not the parent — a hospital’s BACTEC contract does not renegotiate because a segment moves. What changes is the direction of investment. Instrument platforms inside a diagnostics business are funded against menu expansion, because the menu is what the next five years of consumable revenue depends on. Inside an analytical-instruments company they are funded against the returns available in that portfolio.

The second-order risk for laboratories is therefore not continuity. It is roadmap: whether the susceptibility determination that makes a blood culture clinically useful keeps getting faster, or whether it settles at the speed it currently runs at while the fee schedule cuts the code that pays for it.

Companion analyses in this cluster

Three analyses sit alongside it. Microbiology Is the Only Discipline in Diagnostics Where the Price of a Test Is Rising measures the mix effect that made this franchise read as a growth business, and the code split that has now stopped working. Medicare Cut 224 Microbiology Codes by 19.3 Per Cent is the price event itself, in full. The Antibiotic Pipeline Is the Ceiling Under the Microbiology Test Menu explains why the assay menu cannot simply outgrow the problem.

Related research: Global Microbiology Diagnostics Market, 2026–2033; Global In Vitro Diagnostics Market; Global Immunoassay Market; and Global IVD Reagents and Consumables Market, where the instrument-to-reagent ratio is shown to be a property of the contract rather than of the market.

About the method

70% secondary, 30% primary. Segment revenue, utilisation commentary and transaction detail are read from the issuing company: BD’s FY2025 fourth-quarter and full-year results for Diagnostic Solutions revenue and instrument utilisation, bioMérieux’s FY2025 consolidated statements for the disclosed microbiology benchmark, and Bruker’s 2025 accounts. Attribution is built pool by pool with each estimate labelled. No market-research competitor material is cited, quoted or used to set any level.

The primary layer is 41 depth interviews across 12 markets, 26 open-ended tender-cycle interviews, a 158-respondent laboratory survey and structured observation at four conferences. It establishes mechanism and sequence, carries no figure, and the counts are stated so they can be reconciled against programme records.

Sources

• BD — FY2025 fourth quarter and full year results (Diagnostic Solutions revenue; US BACTEC, MAX and COR utilisation above 85% of historical levels; announced combination of Diagnostic Solutions with Waters)
• bioMérieux — FY2025 consolidated financial statements (microbiology and BIOFIRE application revenue)
• Bruker — FY2025 results and 2025 Annual Report (microbiology and MALDI-TOF revenue)
• Danaher — Fourth Quarter and Full Year 2025 Results (Cepheid molecular systems)
• CMS — preliminary CY 2027 Clinical Laboratory Fee Schedule fact sheet (224 microbiology codes; 1,528 priced codes; 15% annual phase-in)
• WHO Global Tuberculosis Report 2025 (culture and molecular case-finding volumes)
• Regulation (EU) 2017/746 on in vitro diagnostic medical devices (Class D transition schedule)

Company and entity links

BD Q813780 · bioMérieux Q2904021 · Bruker Q431454